Olema Pharmaceuticals Inc (OLMA)

$14.08 -0.88 (-5.88%)
Market Cap 1.00B
Revenue (ttm) 0.00
Net Income (ttm) -129.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 8,304,899
Avg Vol 1,785,544
Day's Range N/A - N/A
Shares Out 68.66M
Stochastic %K 1%
Beta 1.92
Analysts Strong Sell
Price Target $43.00

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 651 3316
Website: olema.com
Address:
780 Brannan Street, San Francisco, United States
Asterix_le_Gaulois
Asterix_le_Gaulois Mar. 21 at 3:05 PM
$OLMA NVS buys Synnovation drug... hmmmm, so with this and Kisqali they want to remain a leader in breast cancer treatment... why not also acquire the best estrogen receptor blocker for the complete package?
0 · Reply
THE_MADMAN
THE_MADMAN Mar. 20 at 7:49 AM
$OLMA what's with the aftermarket....
0 · Reply
Keystone1
Keystone1 Mar. 19 at 3:18 PM
$OLMA we’re in a very tough equity market for sure. It’s good to see it up today. Surely it must be way oversold.
0 · Reply
Keystone1
Keystone1 Mar. 18 at 8:38 PM
$OLMA Perhaps management will engage an investment bank to run a M&A process to seek the highest offer. Probably several interested bidders now that Roche is out!
0 · Reply
anachartanalyst
anachartanalyst Mar. 18 at 8:02 PM
$OLMA https://anachart.com/wp-content/uploads/ana_temp/1773864112_soc-img.jpg
0 · Reply
patatechaude
patatechaude Mar. 18 at 5:05 PM
$OLMA Olema seems to have a better drug than Roche had. Buyout in sight IMO. Olema (Palazestrant/OP-1250): Designed as both a SERD and a Complete Estrogen Receptor Antagonist (CERAN). It is considered to have superior potency and superior exposure compared to Giredestrant. Roche (Giredestrant): A potent oral SERD, but it failed to hit the primary endpoint of statistically significant progression-free survival in a key 2026 Phase 3 study. $XBI
0 · Reply
Keystone1
Keystone1 Mar. 18 at 3:17 PM
$OLMA https://finance.yahoo.com/news/olema-oncology-present-preclinical-data-203000695.html
0 · Reply
Keystone1
Keystone1 Mar. 18 at 3:15 PM
$OLMA https://finance.yahoo.com/news/olema-pharmaceuticals-olma-loses-33-133502813.html
0 · Reply
patatechaude
patatechaude Mar. 18 at 1:48 PM
$OLMA Back in my small position. Now stop it and announce buyout.
0 · Reply
Keystone1
Keystone1 Mar. 18 at 1:25 PM
$OLMA Glad to see Goldman Sacks reiterated a BUY!
0 · Reply
Latest News on OLMA
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mar 16, 2026, 7:00 AM EDT - 5 days ago

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

Mar 9, 2026, 1:57 PM EDT - 12 days ago

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

Why Is Olema Pharmaceuticals Stock Dropping On Monday?

Mar 9, 2026, 12:22 PM EDT - 12 days ago

Why Is Olema Pharmaceuticals Stock Dropping On Monday?

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 4:30 PM EST - 18 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 23, 2026, 12:04 PM EST - 26 days ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 13, 2026, 4:47 PM EST - 5 weeks ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Olema Oncology to Participate in Upcoming Investor Conferences

Feb 4, 2026, 4:30 PM EST - 6 weeks ago

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology Announces Departure of Chief Operating and Financial Officer

Jan 30, 2026, 4:01 PM EST - 7 weeks ago

Olema Oncology Announces Departure of Chief Operating and Financial Officer

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 12:05 PM EST - 2 months ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 2 months ago

Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Dec 24, 2025, 9:00 AM EST - 3 months ago

Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Nov 21, 2025, 4:30 PM EST - 4 months ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nov 20, 2025, 4:01 PM EST - 4 months ago

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 18, 2025, 4:51 PM EST - 4 months ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 4 months ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT MRK NVO PFE

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

Nov 18, 2025, 12:01 PM EST - 4 months ago

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

OLMA stock: could today's 197% surge be just the beginning?

Nov 18, 2025, 10:21 AM EST - 4 months ago

OLMA stock: could today's 197% surge be just the beginning?

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Nov 18, 2025, 9:56 AM EST - 4 months ago

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Nov 10, 2025, 7:00 AM EST - 4 months ago

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Oct 30, 2025, 4:30 PM EDT - 5 months ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Oct 30, 2025, 3:25 PM EDT - 5 months ago

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Oct 18, 2025, 3:00 AM EDT - 5 months ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 28, 2025, 7:00 AM EDT - 10 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

May 13, 2025, 4:01 PM EDT - 11 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 25, 2025, 1:00 PM EDT - 11 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Apr 8, 2025, 4:25 PM EDT - 1 year ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 1 year ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Feb 18, 2025, 7:00 AM EST - 1 year ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 1 year ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Top 3 Health Care Stocks That May Explode In Q4

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 10, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Dec 9, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 25, 2024, 5:30 PM EST - 1 year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 15, 2024, 7:01 AM EDT - 2 years ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:02 PM EDT - 2 years ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 8, 2024, 7:02 AM EDT - 2 years ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

Olema Oncology to Participate in Upcoming Investor Conferences in May

May 1, 2024, 7:02 AM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 11, 2024, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Mar 6, 2024, 7:03 AM EST - 2 years ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Asterix_le_Gaulois
Asterix_le_Gaulois Mar. 21 at 3:05 PM
$OLMA NVS buys Synnovation drug... hmmmm, so with this and Kisqali they want to remain a leader in breast cancer treatment... why not also acquire the best estrogen receptor blocker for the complete package?
0 · Reply
THE_MADMAN
THE_MADMAN Mar. 20 at 7:49 AM
$OLMA what's with the aftermarket....
0 · Reply
Keystone1
Keystone1 Mar. 19 at 3:18 PM
$OLMA we’re in a very tough equity market for sure. It’s good to see it up today. Surely it must be way oversold.
0 · Reply
Keystone1
Keystone1 Mar. 18 at 8:38 PM
$OLMA Perhaps management will engage an investment bank to run a M&A process to seek the highest offer. Probably several interested bidders now that Roche is out!
0 · Reply
anachartanalyst
anachartanalyst Mar. 18 at 8:02 PM
$OLMA https://anachart.com/wp-content/uploads/ana_temp/1773864112_soc-img.jpg
0 · Reply
patatechaude
patatechaude Mar. 18 at 5:05 PM
$OLMA Olema seems to have a better drug than Roche had. Buyout in sight IMO. Olema (Palazestrant/OP-1250): Designed as both a SERD and a Complete Estrogen Receptor Antagonist (CERAN). It is considered to have superior potency and superior exposure compared to Giredestrant. Roche (Giredestrant): A potent oral SERD, but it failed to hit the primary endpoint of statistically significant progression-free survival in a key 2026 Phase 3 study. $XBI
0 · Reply
Keystone1
Keystone1 Mar. 18 at 3:17 PM
$OLMA https://finance.yahoo.com/news/olema-oncology-present-preclinical-data-203000695.html
0 · Reply
Keystone1
Keystone1 Mar. 18 at 3:15 PM
$OLMA https://finance.yahoo.com/news/olema-pharmaceuticals-olma-loses-33-133502813.html
0 · Reply
patatechaude
patatechaude Mar. 18 at 1:48 PM
$OLMA Back in my small position. Now stop it and announce buyout.
0 · Reply
Keystone1
Keystone1 Mar. 18 at 1:25 PM
$OLMA Glad to see Goldman Sacks reiterated a BUY!
0 · Reply
erevnon
erevnon Mar. 18 at 11:59 AM
Goldman Sachs maintains Olema Pharmaceuticals $OLMA at Buy and lowers the price target from $38 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DARKP00L
DARKP00L Mar. 18 at 11:56 AM
$OLMA 07:47 on Mar. 18 2026 Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $27 #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 17 at 11:44 PM
$OLMA Share Price: $15.06 Contract Selected: Jul 17, 2026 $15 Calls Buy Zone: $1.83 – $2.26 Target Zone: $3.07 – $3.75 Potential Upside: 59% ROI Time to Expiration: 121 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Keystone1
Keystone1 Mar. 17 at 7:04 PM
$OLMA Hopefully it recovers this afternoon!
0 · Reply
patatechaude
patatechaude Mar. 17 at 4:08 PM
$OLMA Stopped out. It'll go up now.
1 · Reply
Merlintrader
Merlintrader Mar. 17 at 3:35 PM
$OLMA
0 · Reply
Keystone1
Keystone1 Mar. 17 at 1:45 PM
$OLMA Little profit taking after a 13% gain. Wouldn’t surprise me if it closes green, especially so on St. Patrick’s day!
0 · Reply
patatechaude
patatechaude Mar. 17 at 12:20 PM
$XBI $OLMA Completely under the radar. Breast cancel drug could make this little gem a multi-billion revenue biotech.
0 · Reply
Keystone1
Keystone1 Mar. 17 at 11:25 AM
$OLMA https://finance.yahoo.com/news/biotech-stock-nearly-300-draws-230212645.html
0 · Reply
Merlintrader
Merlintrader Mar. 17 at 7:02 AM
$OLMA https://www.merlintrader.com/olema-pharmaceuticals-inc-march17-dd/
0 · Reply
toxicdogie
toxicdogie Mar. 16 at 10:16 PM
$BMNR $NCPL $OLMA $ORBS NCPL watch for a massive splice overnight and tmrw 50-60%++
0 · Reply
FoxyDreams
FoxyDreams Mar. 16 at 8:50 PM
{}@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $ORBS $BMNR $OLMA $NCPL >> on watch as well..
0 · Reply